First-Line Medications for Common Mental Health Disorders
For most common mental health disorders in adults, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) represent the first-line pharmacological treatment, with specific dosing and duration varying by condition.
Major Depressive Disorder (MDD)
Recommended First-Line Agents:
- SSRIs: Sertraline 50-200 mg daily, Citalopram 20-40 mg daily, Escitalopram 10-20 mg daily, Fluoxetine 20-80 mg daily, or Paroxetine 20-50 mg daily 1
- SNRIs: Venlafaxine 37.5-225 mg daily or Duloxetine 40-120 mg daily 1
- Other options: Bupropion SR 100-400 mg daily or Mirtazapine 15-45 mg daily 1
Dosing Frequency: Once daily for most agents; bupropion SR and some formulations require twice-daily dosing 1
Treatment Duration:
- Continue for 4-9 months after satisfactory response for first episode 1
- For patients with 2 or more episodes, longer duration (potentially indefinite) is beneficial 1
- Reassess within 1-2 weeks of initiation, modify if no adequate response within 6-8 weeks 1
Key Considerations: All second-generation antidepressants show similar efficacy; selection should be based on adverse effect profiles, cost, and patient preferences 1
Generalized Anxiety Disorder (GAD)
Recommended First-Line Agents:
- SSRIs: Sertraline, escitalopram, paroxetine, or fluoxetine at standard antidepressant doses 2, 3, 4
- SNRIs: Venlafaxine extended-release or duloxetine 2, 3, 4
Typical Dosing:
Dosing Frequency: Once daily 2, 4
Treatment Duration: Minimum 8-12 weeks for acute treatment; 24-76 weeks for maintenance to prevent relapse 5, 3
Key Considerations: SSRIs and SNRIs show moderate effect sizes (SMD -0.55) compared to placebo 2. Treatment should continue for at least 6 months after remission to prevent relapse 5
Panic Disorder
Recommended First-Line Agents:
- SSRIs: Escitalopram 5-10 mg daily (flexible dosing), sertraline, paroxetine, or fluoxetine 1, 2, 6
- SNRIs: Venlafaxine extended-release 2, 4
Dosing Frequency: Once daily 2, 4
Treatment Duration: 10-12 weeks for acute treatment; longer-term maintenance recommended to prevent relapse 1, 5
Key Considerations: Escitalopram demonstrates faster onset of action compared to citalopram 5. TCAs are equally effective but less well tolerated 6
Social Anxiety Disorder (Social Phobia)
Recommended First-Line Agents:
Dosing Frequency: Once daily 1, 2
Treatment Duration: 12-24 weeks for acute treatment; maintenance therapy for 24+ weeks reduces relapse risk (22% vs 50% placebo) 5
Key Considerations: SSRIs and venlafaxine have weak strength of recommendation with low certainty of evidence, but remain first-line based on available data 1
Obsessive-Compulsive Disorder (OCD)
Recommended First-Line Agents:
- SSRIs: Escitalopram 20 mg daily, sertraline, fluoxetine, paroxetine, or fluvoxamine 5, 6
- TCA: Clomipramine (equally effective but less well tolerated) 6
Dosing Frequency: Once daily 5
Treatment Duration: 12 weeks for acute treatment; 24+ weeks for maintenance (relapse rate 23% vs 52% placebo) 5
Key Considerations: Higher doses of SSRIs are typically required for OCD compared to depression 6
Post-Traumatic Stress Disorder (PTSD)
Recommended First-Line Agents:
Dosing Frequency: Once daily
Treatment Duration: Minimum 12 weeks for acute treatment; longer-term maintenance recommended
Key Considerations: Evidence is derived primarily from SSRI efficacy studies 6
Bipolar Disorder - Acute Mania
Recommended First-Line Agents:
- Mood Stabilizers: Lithium (therapeutic level monitoring required) or Valproate 1
- Atypical Antipsychotics: Aripiprazole, olanzapine, risperidone, quetiapine, or ziprasidone 1
Dosing: Titrate based on response and tolerability; lithium requires therapeutic drug monitoring 1
Dosing Frequency: Varies by agent; typically 1-2 times daily 1
Treatment Duration: Acute stabilization followed by maintenance therapy 1
Key Considerations: Lithium is FDA-approved for ages 12+ for acute mania and maintenance 1. Choice should consider phase of illness, presence of psychotic symptoms, and side effect profile 1
Bipolar Depression
Recommended First-Line Agents:
- Combination therapy: Olanzapine plus fluoxetine (FDA-approved for bipolar depression in adults) 1
- Monotherapy: Lamotrigine or quetiapine 1
Key Considerations: Antidepressants should only be used with concurrent mood stabilizer to prevent manic switch 1. Evidence for bipolar depression treatment is considerably less robust than for acute mania 1
Schizophrenia - Acute Treatment
Recommended First-Line Agents:
- Atypical Antipsychotics: Risperidone, olanzapine, quetiapine, aripiprazole, or ziprasidone 1
- For treatment-resistant cases: Clozapine (requires therapeutic drug monitoring; target plasma level ≥350 ng/mL) 1
Dosing: Titrate to therapeutic range based on response and tolerability 1
Dosing Frequency: 1-2 times daily depending on agent 1
Treatment Duration: Acute stabilization followed by long-term maintenance 1
Key Considerations: Clozapine should be considered after two failed trials of other antipsychotics 1. Metformin should be offered concomitantly with olanzapine or clozapine to attenuate weight gain 1
Adult Attention-Deficit/Hyperactivity Disorder (ADHD)
Note: The provided evidence does not contain specific guideline recommendations for adult ADHD pharmacotherapy. Standard clinical practice typically involves stimulants (methylphenidate, amphetamines) or non-stimulants (atomoxetine, bupropion) as first-line agents, but this falls outside the scope of the provided evidence.
General Principles Across All Conditions
Monitoring:
- Assess patient status, therapeutic response, and adverse effects regularly beginning within 1-2 weeks of initiation 1
- Modify treatment if inadequate response after 6-8 weeks 1
Dose Adjustments:
- Older adults (>65 years) should start at approximately 50% of standard adult starting dose 1
- Renal or hepatic impairment may require dose reduction for specific agents 1
Common Pitfalls: